Preventing Depression in Patients With Macular Degeneration

This study has been completed.
National Institute of Mental Health (NIMH)
Information provided by (Responsible Party):
Thomas Jefferson University Identifier:
First received: July 24, 2002
Last updated: January 7, 2014
Last verified: February 2008
This study will evaluate the effectiveness of a Problem Solving Treatment in preventing depression in elderly patients with age-related macular degeneration (AMD).

Condition Intervention Phase
Macular Degeneration
Behavioral: Problem Solving Treatment
Behavioral: Control
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Preventing Depression in Macular Degeneration

Resource links provided by NLM:

Further study details as provided by Thomas Jefferson University:

Primary Outcome Measures:
  • Depression [ Time Frame: 6 Months ] [ Designated as safety issue: No ]

Enrollment: 206
Study Start Date: February 2001
Study Completion Date: January 2006
Primary Completion Date: January 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Problem Solving Treatment
Behavioral: Problem Solving Treatment
Brief Cognitive Behavioral Therapy
Active Comparator: 2
Behavioral: Control
No treatment control

Detailed Description:

AMD is the most common cause of blindness in older adults. The disease limits the ability to read, see familiar faces, and walk independently. Almost 2 million persons (about 5 percent of the U.S. population over age 65) are now affected, and this number will triple by the year 2020. This study will target patients with neovascular AMD (NV-AMD), a form of AMD which can lead to sudden vision loss, substantial disability, and depression. Because depression is itself disabling and not likely to be recognized nor treated by ophthalmologists, preventing depression in people with NV-AMD is important.

Patients are randomly assigned to either PST or a usual care control condition. The primary outcome measure is a DSM-IV diagnosis of depression. Patients are evaluated at baseline, Month 2 (immediately post-intervention), Month 6 (for the primary efficacy analysis), and Month 12 (to evaluate sustained effects). The study will also assess the impact of PST on levels of disability and vision-related quality of life.


Ages Eligible for Study:   65 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Bilateral macular degeneration
  • Visual acuity of 20/40 or worse in better eye
  • Residence within 40 miles of Wills Eye Hospital in Philadelphia, PA
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00042211

United States, Pennsylvania
Thomas Jefferson University
Philadelphia, Pennsylvania, United States, 19107
Sponsors and Collaborators
Thomas Jefferson University
National Institute of Mental Health (NIMH)
Principal Investigator: barry rovner, md Thomas Jefferson University
  More Information

Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Thomas Jefferson University Identifier: NCT00042211     History of Changes
Other Study ID Numbers: R01MH061331  DATR A4-GPS 
Study First Received: July 24, 2002
Last Updated: January 7, 2014
Health Authority: United States: Federal Government

Keywords provided by Thomas Jefferson University:
Depressive Disorder

Additional relevant MeSH terms:
Depressive Disorder
Macular Degeneration
Behavioral Symptoms
Eye Diseases
Mental Disorders
Mood Disorders
Retinal Degeneration
Retinal Diseases processed this record on February 11, 2016